FAK is frequently overexpressed in various types of cancer, including breast, ovarian, colon, and prostate cancers. Its overexpression is often correlated with poor prognosis and increased metastatic potential. FAK promotes cancer cell survival, invasion, and metastasis by activating multiple downstream signaling pathways, including the PI3K/Akt, MAPK, and Rho GTPase pathways.
